Anti inflammatory Drug Market

Anti-inflammatory Drug Market Size (2023-2028)

The Global anti-inflammatory drug market was estimated to be worth USD 115.82 billion in 2023 and is anticipated to grow at a CAGR of 7.10% throughout the forecast period, reaching USD 163.21 billion by 2028.

Anti-inflammatory drug market share insights:

• Based on Drug class, the Anti-inflammatory drug segment dominate the market in 2022.
• Based on formulation type, the oral formulation segment dominates the market globally and is expected to grow at a CAGR of 8.9% during the forecasted period.
• In 2022, the North American market have the highest CAGR 39.05%, and will have the greatest share of the global market.

Impact of Covid-19 on Anti-inflammatory Drug Market:

The pandemic crisis positively as well as negatively affected the anti-inflammatory drug market. The novel coronavirus induces inflammation in the infected person which may cause severe pneumonia with increased inflammation. Inflammation causes a rise of various diseases such as acute lung injury, acute respiratory disorder, and other complications which need the use of anti-inflammatory drugs for treatment. There was an increase in demand for certain anti-inflammatory drugs such as corticosteroids like dexamethasone and tocilizumab. Due to increases in the cases such as acute lung injury, respiratory disorder, and organ dysfunction, there was an increase in the research and development of anti-inflammatory drugs for the treatment of inflammation caused by coronavirus. Many clinical trials are currently underway to alleviate this destructive inflammation thus increase in the research and development activity associated with anti-inflammatory drugs favors the market growth during a worldwide health crisis.

The pandemic disrupted the global supply chain including the pharmaceutical industries, during the pandemic social isolation, lockdown measures and disruption in the manufacturing process affected the production and distribution of various drugs which include anti-inflammatory drugs, due to the disruption in the process led to a shortage and supply chain challenge for pharmaceutical companies. even though the anti-inflammatory drug market faces lots of challenges due to the pandemic but it also opens up a new opportunity for the anti-inflammatory drug market, it stimulates an increase in the processes of research and development which causes an increase in revenue of the anti-inflammatory drug market in upcoming years.

MARKET DRIVERS:

One of the major driving factors which boosts the demand for anti-inflammatory drugs is the increasing prevalence of inflammatory diseases which causes an increased demand for anti-inflammatory drugs. As per the CDC an estimated 90 million people globally diagnosed with arthritis by 2028, there is an increase in the prevalence of diseases such as rheumatoid arthritis, and ulcerative colitis which causes an increase in the demand for the anti-inflammatory drug. The factor which causes a rise in inflammatory diseases are the aging population, lifestyle changes, and environmental factor that contribute to an increase in the prevalence of inflammatory changes, at a rapid pace the lifestyle of people changes which include physical inactivity and inappropriate diet also the environmental conditions largely affect the rising of inflammatory diseases this factor led to increase in the demand for the anti-inflammatory drugs which led to boosting the growth of the anti-inflammatory drug market during the forecasted period.

The second major driver driving the growth of the anti-inflammatory drug market is technological advancement. Now due to innovation and digitalization, advanced technology has been used in the pharmaceutical manufacturing industries. The development of targeted drug delivery systems with the help of technology increases day by day, it is projected the technological advancement in drug delivery systems will be reached USD 72.63 billion by 2028, pharmaceutical companies now increase investment in research and development of new anti-inflammatory drugs which include development of novel drug classes, advanced targeted therapies and more personalized treatment, this advancement in technology contribute to the expansion of the anti-inflammatory drug market during the projected period.

The development of new drug administration methods is another major factor boosting the growth of the anti-inflammatory drug market. The development of new drug administration methods can improve the convenience of patient, compliance which led to an increase in the use of anti-inflammatory drugs. This is a convenient and user-friendly method for the patients. This method can provide pharmaceutical companies with a competitive advantage, by introducing unique and patent-protected technologies companies can capture a larger market share. This drug administration method can improve efficiency, enhance patient convenience, and open new opportunities for anti-inflammatory drugs, thus this is another factor boosting the growth of the market during the forecasted period.

The increasing prevalence of autoimmune and respiratory disorders, mediation under development, an increase in the use of anti-inflammatory pharmaceuticals, technological advancement, and innovation are some of the factors propelling the growth of the anti-inflammatory drug market.

MARKET RESTRAINTS:

Although there is numerous factor driving the growth of the anti-inflammatory drug market there is some factor which is negatively impacting the anti-inflammatory drug market and hindering its growth. There is an increase in the prevalence of inflammatory diseases which causes a vast amount of usage of anti-inflammatory drugs, by the consistent usage of these anti-inflammatory drugs rises various side-effects such as dizziness, stomach ulcers, allergic reaction such side effect reduces the usage of anti-inflammatory drugs for treatment which led to restraining the growth of the anti-inflammatory drug market.

Patent expiration of anti-inflammatory drugs is another factor that restrains the growth of the anti-inflammatory drug market. When the patent protection of branded anti-inflammatory drugs expires the generic version of the drug can enter into the market and sell at a cheaper rate, this availability of lower-cost generic alternatives led to a decrease in the market share of the anti-inflammatory drug market. These factors lower the market growth of anti-inflammatory drugs.

REPORT COVERAGE:

This research report on the Anti-inflammatory drug Market has been segmented and sub-segmented based on the drug class, Treatment, route of administration, sales channel and  Region

Anti-inflammatory drug Market- Based on Drug class

• Anti-inflammatory biologics
• Nonsteroidal anti-inflammatory drugs
• Corticosteroids
• Other drug class

Based on drug class the anti-inflammatory drug market categorizes into anti-inflammatory biologics, Nonsteroidal anti-inflammatory drugs, corticosteroids, and other drug classes. The anti-inflammatory biologic segment dominate the market during the forecasted period. This segment was accounted for 44.7% of the market share in 2022 and expected to continue to grow at the fastest CAGR during the forecasted period. This segment target specific inflammatory pathway and help to reduce inflammation and provide beneficial relief from symptom, this factor led to dominate the market by anti-inflammatory biologics during the forecasted period.

The non-steroidal anti-inflammatory drug segment also expects to dominate the market during the forecasted period as this is a primary treatment option for pain and inflammation thus this segment also expects to dominate the market during the forecasted period.

Anti-inflammatory Drug Market- Based on Treatment

• Arthritis
• Inflammatory bowel disease (IBD)
• Chronic obstructive pulmonary disease
• Multiple sclerosis
• Other treatments

Based on treatment, the Arthritis segment is expected to dominate the market during the projected period. This segment is expected to register over USD 65.03 billion by 2028. The anti-inflammatory drug is the best-suited option help to reduce inflammation and improve joint function caused by arthritis. These drugs are also beneficial for slowing down the disease progression by managing the symptoms that allow patients to perform daily activities with greater ease thus this segment is projected to grow at the fastest CAGR during the forecasted period.

The multiple sclerosis segment also growing at a healthy CAGR during the forecasted period. Increased government support, rise in healthcare expenditure, and growing investment in research and development for multiple sclerosis medication this factor fuels the growth of this segment during the forecasted period.

Anti-inflammatory Drug Market- Based on Route of Administration

• Oral
• Topical
• Injection
• Intranasal

According to the route of administration method, the anti-inflammatory drug market is categorized into oral, topical, injection, and intranasal segments. The oral segment is expected to grow at the fastest CAGR at 8.9% by 2028. This route is suitable to the patient for proper medication, this includes medication in the form of tablets, capsules. As this is self-administrated and composed in the appropriate proportion that enables individuals for the correct proportion of dosage, thus this segment is expected to dominate the market during the projected period.

The Injection segment is also expected to grow at the fastest CAGR during the forecasted period. The pandemic situation also positively impacted this segment, also a maximum of anti-inflammatory biologics administrated via subcutaneous or intravenous route this is the primary reason for the growth of this segment during the forecasted period.

Anti-inflammatory drug Market- Based on Sales channel

• Prescription
• Over the counter

Based on the sales channel, the prescription segment is expected to dominate the market during the forecasted period. As this segment was accounted for USD 57 billion in market revenue in 2022 and expected to continue to grow at the highest CAGR during the projected period. As prescription-based anti-inflammatory drugs are appropriately prescribed under medical supervision and also optimize patient safety and proper medication thus this segment is expected to dominate the market during the forecasted period.

The counter segment is also expected to dominate the market at a healthy CAGR during the forecasted period.

Anti-inflammatory Drug Market - Based on Region:

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa

Based on geographical region, the North American region is the fastest-growing region that dominates the market during the forecasted period. This region accounted for 39.5% market share in 2022. The increasing inflammatory diseases due to changes in lifestyle, physical inactivity, and also increasing population are the major reason to boost the market growth of the anti-inflammatory drug market in this region. The advanced healthcare infrastructure and innovation in research and development facilities in this region boost the market growth of the drug in the North American region.

Europe is the second largest region that dominates the market during the forecasted period. The large amount of favoring policies for biosimilars, and approval of new products are major factors projected to boost the demand in Europe.

The Asia-Pacific region is also expected to grow at a healthy CAGR during the forecasted period. The increasing prevalence of inflammatory diseases, lifestyle changes, and rising uptake of OTC anti-inflammatory drugs are some of the factors boosting the growth of the anti-inflammatory drug market in this region.

The Latin America, Middle East-Africa region is also expected to grow at steady CAGR during the forecasted period. The improving healthcare infrastructure and rise in the incidence of diseases such as rheumatoid arthritis boost the market growth for anti-inflammatory drugs in this region.

KEY MARKET PLAYERS:

The worldwide prominent key player in the anti-inflammatory drug market are Amgen, Biogen, Bristol Myers Squibb, GlaxoSmithKline, Johnson& Johnson, Novartis, Pfizer, Aurobindo Pharma, AstraZeneca, Bayer, Bio-Thera Solutions, Cadila-Pharmaceuticals, Cipla, Dr.Reddy’s Laboratories, and Gilead Sciences.

RECENT MARKET DEVELOPMENTS:

• In May 2023, RINVOQ, manufactured by AbbVie Inc., has been given FDA approval for the treatment of individuals with moderately to highly active Crohn's disease. This product approval is anticipated to assist the business in improving its anti-inflammatory medicine product portfolio and accelerating revenue growth.
• In March 2022, The purchase of Arena Pharmaceuticals by Pfizer Inc. The company may expand and improve its product line in cardiology, dermatology, and gastrointestinal thanks to this acquisition. The company was able to expand its capabilities and domain knowledge in the inflammation and immunology segment thanks to this strategic purchase.